KR20090052346A - 인자 ｘａ 억제제를 포함하는 복수의 소형 정제를 포함하는제약 조성물 - Google Patents

인자 ｘａ 억제제를 포함하는 복수의 소형 정제를 포함하는제약 조성물 Download PDF

Info

Publication number
KR20090052346A
KR20090052346A KR1020097005035A KR20097005035A KR20090052346A KR 20090052346 A KR20090052346 A KR 20090052346A KR 1020097005035 A KR1020097005035 A KR 1020097005035A KR 20097005035 A KR20097005035 A KR 20097005035A KR 20090052346 A KR20090052346 A KR 20090052346A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
modified release
release pharmaceutical
factor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097005035A
Other languages
English (en)
Korean (ko)
Inventor
오마르 아브델파타흐 아부-베이커
용 휴
킴벌리 앤 라메이
로버트 프랜시스 레포스키
레난 판
캠레쉬 라메쉬챈드라 파텔
라훌 파라쉐르 슈클라
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090052346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20090052346A publication Critical patent/KR20090052346A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097005035A 2006-09-12 2007-09-10 인자 ｘａ 억제제를 포함하는 복수의 소형 정제를 포함하는제약 조성물 Withdrawn KR20090052346A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82531406P 2006-09-12 2006-09-12
US60/825,314 2006-09-12

Publications (1)

Publication Number Publication Date
KR20090052346A true KR20090052346A (ko) 2009-05-25

Family

ID=38835794

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097005035A Withdrawn KR20090052346A (ko) 2006-09-12 2007-09-10 인자 ｘａ 억제제를 포함하는 복수의 소형 정제를 포함하는제약 조성물

Country Status (16)

Country Link
US (1) US20090285887A1 (enExample)
EP (1) EP2061439A1 (enExample)
JP (1) JP2010502762A (enExample)
KR (1) KR20090052346A (enExample)
CN (1) CN101516355A (enExample)
AR (1) AR062721A1 (enExample)
AU (1) AU2007296311A1 (enExample)
BR (1) BRPI0716234A2 (enExample)
CA (1) CA2662542A1 (enExample)
CL (1) CL2007002618A1 (enExample)
EA (1) EA200970267A1 (enExample)
IL (1) IL197295A0 (enExample)
MX (1) MX2009002669A (enExample)
PE (1) PE20080661A1 (enExample)
TW (1) TW200824723A (enExample)
WO (1) WO2008031782A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2010151745A1 (en) * 2009-06-25 2010-12-29 Elite Laboratories, Inc. Oral dosage forms
SI3246021T1 (sl) * 2010-02-25 2020-03-31 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
AU2015271995A1 (en) * 2010-02-25 2016-01-21 Bristol-Myers Squibb Holdings Ireland Apixaban formulations
RU2013113627A (ru) * 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
MX370873B (es) 2010-10-15 2020-01-08 Brain Sentinel Inc Metodo y aparato para detectar convulsiones.
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
WO2013174498A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
WO2014033077A1 (en) 2012-08-28 2014-03-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
US20190046449A1 (en) * 2016-02-25 2019-02-14 Mylan Inc. A unique high-shear granulation process for improved bioavailability of rivaroxaban
GB201721065D0 (en) * 2017-12-15 2018-01-31 Ondosis Ab Delivery device for drug pellets
WO2025150072A1 (en) * 2024-01-13 2025-07-17 Pulse Pharmaceuticals Pvt Ltd A stable oral pro-dispersion formulation and implementations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법

Also Published As

Publication number Publication date
CL2007002618A1 (es) 2008-03-14
CN101516355A (zh) 2009-08-26
EP2061439A1 (en) 2009-05-27
WO2008031782A1 (en) 2008-03-20
TW200824723A (en) 2008-06-16
EA200970267A1 (ru) 2009-08-28
AU2007296311A1 (en) 2008-03-20
JP2010502762A (ja) 2010-01-28
IL197295A0 (en) 2009-12-24
BRPI0716234A2 (pt) 2013-10-15
CA2662542A1 (en) 2008-03-20
AR062721A1 (es) 2008-11-26
MX2009002669A (es) 2009-03-24
PE20080661A1 (es) 2008-06-12
US20090285887A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
KR20090052346A (ko) 인자 ｘａ 억제제를 포함하는 복수의 소형 정제를 포함하는제약 조성물
JP5985719B2 (ja) 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法
EP1441713B1 (en) Modified release tamsulosin tablets
CN101460154B (zh) 包含抗血小板剂和抑酸剂的口服剂型
JP5570426B2 (ja) 固形医薬組成物
JP5666471B2 (ja) 固形製剤
CN103356614A (zh) 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良安全性的方法
CN102209546A (zh) 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
JPWO2017018473A1 (ja) 錠剤
TW200817000A (en) New paediatric indications for direct thrombin inhibitors
MX2011013091A (es) Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel.
JP2023517844A (ja) ベンズイミダゾール誘導体化合物を含有する医薬組成物
CN102209545A (zh) 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
CN109414423A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
KR20160027078A (ko) 라놀라진 및 드로네다론의 제약 조성물
EP4297733A1 (en) Fixed-dose pharmaceutical compositions
JP6122879B2 (ja) 固形製剤
TW202313072A (zh) 檸檬酸鐵之兒科調配物
BR112014007876B1 (pt) Forma de dosagem, composição, processo para preparação de uma composição, uso de uma composição
HK1162927A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
HK1157242A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
HK1158496A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
KR20100063068A (ko) 서방형 약학 제제
HK1190083A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
HK1158543A (en) Solid pharmaceutical composition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090311

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid